A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.
The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.
In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold standard for colon cancer screening. Besides spotting tumors, colonoscopies can prevent the disease by removing precancerous growths called polyps.
But some people avoid the exam because of the hassle of getting time off work or the day-ahead preparation that involves drinking a strong laxative to empty the bowels.
Related articles:
Related suggestion:
The Kentucky Derby in the words of the winners, from Smith to EspinozaHamas to send delegation to Egypt for truce talksFrat boys at UNC Chapel Hill surround American flag in protection as pro Palestine mob runs wildIraqi PM vows to diversify national economyIraqi PM vows to diversify national economyChina expresses grave concerns over Japan's planned export controlsChinese vice president meets Argentine foreign ministerIran condemns sanctions by US, Britain, CanadaChina promoting rapid development of commercial space industry: CNSADPRK top leader attends special concert by Chinese traditional orchestra
3.3189s , 6499.7421875 kb
Copyright © 2024 Powered by Colon cancer blood test offers new screening option ,Global Genesis news portal